Anti-proliferative activity of 25-hydroxyvitamin D3 in human prostate cells

Molecular and Cellular Endocrinology

Volumn 382, Issue 2, 2014, Pages 960-970

  Munetsuna, Eiji ^a,b   Kawanami, Rie ^a   Nishikawa, Miyu ^a   Ikeda, Shinnosuke ^a   Nakabayashi, Sachie ^a   Yasuda, Kaori ^a   Ohta, Miho ^c   Kamakura, Masaki ^a   Ikushiro, Shinichi ^a   Sakaki, Toshiyuki ^a  

^a TOYAMA PREFECTURAL UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

^c Soai University   (Japan)

Author keywords

Anti proliferative activity; CYP24A1; Prostate; Vitamin D receptor; Vitamin D3

Indexed keywords

CALCIFEDIOL; CALCITRIOL; CYSTATIN; CYSTATIN D; CYSTATIN M; SEMAPHORIN; SEMAPHORIN 3B; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CELL CULTURE; CELL GROWTH; CELL IMMORTALIZATION; CONTROLLED STUDY; CYP27B1 GENE; DNA MICROARRAY; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; GENE TRANSLOCATION; HUMAN; HUMAN CELL; HYDROXYLATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROTEIN BINDING; PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; VDR GENE;

1Α,25(OH)(2)D(3); 1Α,25-DIHYDROXY VITAMIN D(3); 1Α,25-DIHYDROXYVITAMIN D(3); 25(OH) D(3); 25-HYDROXYVITAMIN D(3); ANTI-PROLIFERATIVE ACTIVITY; BOVINE PITUITARY EXTRACT; BPE; CYP24A1; GAPDH; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HPLC; LC-MS; LIQUID CHROMATOGRAPHY MASS SPECTROSCOPY; PROSTATE; RETINOID X RECEPTOR; RXR; SIRNA; SMALL INTERFERING RNA; VDR; VITAMIN D RECEPTOR; VITAMIN D(3);

CALCIFEDIOL; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTATIN M; CYSTATINS; GENE EXPRESSION REGULATION; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; PROSTATE; PROTEIN BINDING; RECEPTORS, CALCITRIOL; RNA, MESSENGER; RNA, SMALL INTERFERING; SEMAPHORINS; SIGNAL TRANSDUCTION; STEROID HYDROXYLASES; TRITIUM;

EID: 84890204182     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.11.014     Document Type: Article

References (42)

1. Ahonen M.H., Tenkanen L., Teppo L., Hakama M., Tuohimaa P. Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control 2000, 11:847-852.
2. Akiyoshi-Shibata M., Sakaki T., Ohyama Y., Noshiro M., Okuda K., Yabusaki Y. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. A study with the mature enzyme expressed in Escherichia coli. Eur. J. Biochem. 1994, 224:335-343.
3. Alvarez-Diaz S., Valle N., Garcia J.M., Pena C., Freije J.M., Quesada V., Astudillo A., Bonilla F., Lopez-Otin C., Munoz A. Cystatin D is a candidate tumor suppressor gene induced by vitamin D in human colon cancer cells. J. Clin. Invest. 2009, 119:2343-2358.
4. Barger-Lux M.J., Heaney R.P., Lanspa S.J., Healy J.C., DeLuca H.F. An investigation of sources of variation in calcium absorption efficiency. J. Clin. Endocrinol. Metab. 1995, 80:406-411.
5. Bikle D.D., Nemanic M.K., Gee E., Elias P. 1,25-Dihydroxyvitamin D3 production by human keratinocytes. Kinetics and regulation. J. Clin. Invest. 1986, 78:557-566.
6. Bouillon R., Okamura W.H., Norman A.W. Structure-function relationships in the vitamin D endocrine system. Endocr. Rev. 1995, 16:200-257.
7. Chen X., Cao X., Dong W., Xia M., Luo S., Fan Q., Xie J. Cystatin M expression is reduced in gastric carcinoma and is associated with promoter hypermethylation. Biochem. Biophys. Res. Commun. 2010, 391:1070-1074.
8. Dusso A.S., Brown A.J., Slatopolsky E. Vitamin D. Am. J. Physiol. Renal Physiol. 2005, 289. F8-28.
9. Freedman L.P. Transcriptional targets of the vitamin D3 receptor-mediating cell cycle arrest and differentiation. J. Nutr. 1999, 129:581S-586S.
10. Hawkins G.A., Cramer S.D., Zheng S.L., Isaacs S.D., Wiley K.E., Chang B.L., Bleecker E.R., Walsh P.C., Meyers D.A., Isaacs W.B., Xu J. Sequence variants in the human 25-hydroxyvitamin D3 1-alpha-hydroxylase (CYP27B1) gene are not associated with prostate cancer risk. Prostate 2002, 53:175-178.
11. Holick M.F., Schnoes H.K., DeLuca H.F. Identification of 1,25-dihydroxycholecalciferol, a form of vitamin D3 metabolically active in the intestine. Proc. Natl. Acad. Sci. USA 1971, 68:803-804.
12. Hsu J.Y., Feldman D., McNeal J.E., Peehl D.M. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 2001, 61:2852-2856.
13. Kemmis C.M., Salvador S.M., Smith K.M., Welsh J. Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J. Nutr. 2006, 136:887-892.
14. Krishnan A.V., Shinghal R., Raghavachari N., Brooks J.D., Peehl D.M., Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004, 59:243-251.
15. Lawson D.E., Fraser D.R., Kodicek E., Morris H.R., Williams D.H. Identification of 1,25-dihydroxycholecalciferol, a new kidney hormone controlling calcium metabolism. Nature 1971, 230:228-230.
16. Lou Y.R., Laaksi I., Syvala H., Blauer M., Tammela T.L., Ylikomi T., Tuohimaa P. 25-hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. Faseb. J. 2004, 18:332-334.
17. Munetsuna E., Hojo Y., Hattori M., Ishii H., Kawato S., Ishida A., Kominami S.A., Yamazaki T. Retinoic acid stimulates 17beta-estradiol and testosterone synthesis in rat hippocampal slice cultures. Endocrinology 2009, 150:4260-4269.
18. Munetsuna E., Nakabayashi S., Kawanami R., Yasuda K., Ohta M., Arai M.A., Kittaka A., Chen T., Kamakura M., Ikushiro S., Sakaki T. Mechanism of the anti-proliferative Action of 25-Hydroxy-19-nor-vitamin D3 in human prostate cells. J. Mol. Endocrinol 2011.
19. Norman A.W., Myrtle J.F., Midgett R.J., Nowicki H.G., Williams V., Popjak G. 1,25-dihydroxycholecalciferol: identification of the proposed active form of vitamin D3 in the intestine. Science 1971, 173:51-54.
20. Peehl D.M., Krishnan A.V., Feldman D. Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. J. Nutr. 2003, 133:2461S-2469S.
21. Peng X., Hawthorne M., Vaishnav A., St-Arnaud R., Mehta R.G. 25-Hydroxyvitamin D3 is a natural chemopreventive agent against carcinogen induced precancerous lesions in mouse mammary gland organ culture. Breast Cancer Res. Treat. 2009, 113:31-41.
22. Polek T.C., Weigel N.L. Vitamin D and prostate cancer. J. Androl. 2002, 23:9-17.
23. Prufer K., Barsony J. Retinoid X receptor dominates the nuclear import and export of the unliganded vitamin D receptor. Mol. Endocrinol. 2002, 16:1738-1751.
24. Pulukuri S.M., Gorantla B., Knost J.A., Rao J.S. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene 2009, 28:2829-2838.
25. Racz A., Barsony J. Hormone-dependent translocation of vitamin D receptors is linked to transactivation. J. Biol. Chem. 1999, 274:19352-19360.
26. Ritter C.S., Armbrecht H.J., Slatopolsky E., Brown A.J. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int. 2006, 70:654-659.
27. Rolny C., Capparuccia L., Casazza A., Mazzone M., Vallario A., Cignetti A., Medico E., Carmeliet P., Comoglio P.M., Tamagnone L. The tumor suppressor semaphorin 3B triggers a prometastatic program mediated by interleukin 8 and the tumor microenvironment. J. Exp. Med. 2008, 205:1155-1171.
28. Sakaki T., Sawada N., Nonaka Y., Ohyama Y., Inouye K. Metabolic studies using recombinant escherichia coli cells producing rat mitochondrial CYP24 can convert 1alpha,25-dihydroxyvitamin D3 to calcitroic acid. Eur. J. Biochem. 1999, 262:43-48.
29. Sakaki T., Sawada N., Komai K., Shiozawa S., Yamada S., Yamamoto K., Ohyama Y., Inouye K. Dual metabolic pathway of 25-hydroxyvitamin D3 catalyzed by human CYP24. Eur. J. Biochem. 2000, 267:6158-6165.
30. Sakaki T., Kagawa N., Yamamoto K., Inouye K. Metabolism of vitamin D3 by cytochromes P450. Front Biosci. 2005, 10:119-134.
31. Sawada N., Sakaki T., Ohta M., Inouye K. Metabolism of vitamin D(3) by human CYP27A1. Biochem. Biophys. Res. Commun. 2000, 273:977-984.
32. Sawada N., Kusudo T., Sakaki T., Hatakeyama S., Hanada M., Abe D., Kamao M., Okano T., Ohta M., Inouye K. Novel metabolism of 1 alpha,25-dihydroxyvitamin D3 with C24-C25 bond cleavage catalyzed by human CYP24A1. Biochemistry 2004, 43:4530-4537.
33. Schwartz G.G., Whitlatch L.W., Chen T.C., Lokeshwar B.L., Holick M.F. Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3. Cancer Epidemiol. Biomarkers Prev. 1998, 7:391-395.
34. Shridhar R., Zhang J., Song J., Booth B.A., Kevil C.G., Sotiropoulou G., Sloane B.F., Keppler D. Cystatin M suppresses the malignant phenotype of human MDA-MB-435S cells. Oncogene 2004, 23:2206-2215.
35. Skowronski R.J., Peehl D.M., Feldman D. Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 1993, 132:1952-1960.
36. Urushino N., Nakabayashi S., Arai M.A., Kittaka A., Chen T.C., Yamamoto K., Hayashi K., Kato S., Ohta M., Kamakura M., Ikushiro S., Sakaki T. Kinetic studies of 25-hydroxy-19-nor-vitamin D3 and 1 alpha,25-dihydroxy-19-nor-vitamin D3 hydroxylation by CYP27B1 and CYP24A1. Drug Metab. Dispos. 2007, 35:1482-1488.
37. Wang L., Whitlatch L.W., Flanagan J.N., Holick M.F., Chen T.C. Vitamin D autocrine system and prostate cancer. Recent Results Cancer Res. 2003, 164:223-237.
38. Wang T.T., Tavera-Mendoza L.E., Laperriere D., Libby E., MacLeod N.B., Nagai Y., Bourdeau V., Konstorum A., Lallemant B., Zhang R., Mader S., White J.H. Large-scale in silico and microarray-based identification of direct 1,25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 2005, 19:2685-2695.
39. Whitlatch L.W., Young M.V., Schwartz G.G., Flanagan J.N., Burnstein K.L., Lokeshwar B.L., Rich E.S., Holick M.F., Chen T.C. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. J. Steroid Biochem. Mol. Biol. 2002, 81:135-140.
40. Xie Z., Munson S.J., Huang N., Portale A.A., Miller W.L., Bikle D.D. The mechanism of 1,25-dihydroxyvitamin D(3) autoregulation in keratinocytes. J. Biol. Chem. 2002, 277:36987-36990.
41. Yang E.S., Burnstein K.L. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. J. Biol. Chem. 2003, 278:46862-46868.
42. Zierold C., Darwish H.M., DeLuca H.F. Two vitamin D response elements function in the rat 1,25-dihydroxyvitamin D 24-hydroxylase promoter. J. Biol. Chem. 1995, 270:1675-1678.